Diffusion magnetic resonance imaging: A biomarker for treatment response in oncology

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4104-4109

  Hamstra, Daniel A ^a   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARMUSTINE; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; RADIOACTIVE MICROSPHERE; YTTRIUM 90;

BONE CANCER; BRAIN INFARCTION; BRAIN TUMOR; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; EWING SARCOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; MEMBRANE PERMEABILITY; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SPINE CANCER; STROKE; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS CANCER; WATER FLOW; ANIMAL; METABOLISM; METHODOLOGY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 34748865456     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9610     Document Type: Review

References (56)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
2. Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245-3251, 2006
3. Choi H, Charnsangavej C, de Castro Faria S, et al: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183: 1619-1628, 2004
4. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
5. Weber WA: Positron emission tomography as an imaging biomarker. J Clin Oncol 24:3282-3292, 2006
6. Sorensen AG: Magnetic resonance as a cancer imaging biomarker. J Clin Oncol 24:3274-3281, 2006
7. Hylton N: Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24:3293-3298, 2006
8. Daisne JF, Duprez T, Weynand B, et al: Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233:93-100, 2004
9. Mukherji SK, Wolf GT: Evaluation of head and neck squamous cell carcinoma after treatment. AJNR Am J Neuroradiol 24:1743-1746, 2003
10. O'Connor JP, Jackson A, Parker GJ, et al: DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189-195, 2007
11. Masdeu JC, Irimia P, Asenbaum S, et al: EFNS guideline on neuroimaging in acute stroke: Report of an EFNS task force. Eur J Neurol 13:1271-1283, 2006
12. Le Bihan D, Breton E, Lallemand D, et al: Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168:497-505, 1988
13. Schaefer PW, Grant PE, Gonzalez RG: Diffusion-weighted MR imaging of the brain. Radiology 217:331-345, 2000
14. Armitage PA, Schwindack C, Bastin ME, et al: Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. Magn Reson Imaging 25:303-310, 2007
15. Ross BD, Chenevert TL, Kim B, et al: Magnetic resonance imaging and spectroscopy: Application to experimental neuro-oncology. Q Magn Reson Biol Med 1:89-106, 1994
16. Zhao M, Pipe JG, Bonnett J, et al: Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73:61-64, 1996
17. Chenevert TL, McKeever PE, Ross BD: Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3:1457-1466, 1997
18. Chenevert TL, Stegman LD, Taylor JM, et al: Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029-2036, 2000
19. Hamstra DA, Lee KC, Tychewicz JM, et al: The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 10:916-928, 2004
20. Hall DE, Moffat BA, Stojanovska J, et al: Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 10:7852-7859, 2004
21. Moffat BA, Chenevert TL, Meyer CR, et al: The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8:259-267, 2006
22. Lee KC, Hall DE, Hoff BA, et al: Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 66:4687-4692, 2006
23. Lyng H, Haraldseth O, Rofstad EK: Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828-836, 2000
24. Chinnaiyan AM, Prasad U, Shankar S, et al: Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 97:1754-1759, 2000
25. Roth Y, Tichler T, Kostenich G, et al: High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 232:685-692, 2004
26. Thoeny HC, De Keyzer F, Chen F, et al: Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7:779-787, 2005
27. Galons JP, Altbach MI, Paine-Murrieta GD, et al: Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1:113-117, 1999
28. Mardor Y, Roth Y, Lidar Z, et al: Monitoring response to convection-enhanced Taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61:4971-4973, 2001
29. Mardor Y, Pfeffer R, Spiegelmann R, et al: Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21:1094-1100, 2003
30. Tomura N, Narita K, Izumi J, et al: Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: Possible prediction of treatment response. J Comput Assist Tomogr 30:496-500, 2006
31. Schubert MI, Wilke M, Muller-Weihrich S, et al: Diffusion-weighted magnetic resonance imaging of treatment-associated changes in recurrent and residual medulloblastoma: Preliminary observations in three children. Acta Radiol 47:1100-1104, 2006
32. Moffat BA, Chenevert TL, Lawrence TS, et al: Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102:5524-5529, 2005
33. Hamstra DA, Chenevert TL, Moffat BA, et al: Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102:16759-16764, 2005
34. Dzik-Jurasz A, Domenig C, George M, et al: Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 360:307-308, 2002
35. Kremser C, Judmaier W, Hein P, et al: Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther Onkol 179:641-649, 2003
36. Theilmann RJ, Borders R, Trouard TP, et al: Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831-837, 2004
37. Kamel IR, Bluemke DA, Eng J, et al: The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17:505-512, 2006
38. Deng J, Miller FH, Rhee TK, et al: Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17:1195-1200, 2006
39. Kamel IR, Reyes DK, Liapi E, et al: Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 18:49-56, 2007
40. Pickles MD, Gibbs P, Lowry M, et al: Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24:843-847, 2006
41. Yankeelov TE, Lepage M, Chakravarthy A, et al: Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: Initial results. Magn Reson Imaging 25:1-13, 2007
42. Byun WM, Shin SO, Chang Y, et al: Diffusion-weighted MR imaging of metastatic disease of the spine: Assessment of response to therapy. AJNR Am J Neuroradiol 23:906-912, 2002
43. Hayashida Y, Yakushiji T, Awai K, et al: Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol 16:2637-2643, 2006
44. Uhl M, Saueressig U, van Buiren M, et al: Osteosarcoma: Preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 41:618-623, 2006
45. Liapi E, Kamel IR, Bluemke DA, et al: Assessment of response of uterine fibroids and myometrium to embolization using diffusion-weighted echoplanar MR imaging. J Comput Assist Tomogr 29:83-86, 2005
46. Jacobs MA, Herskovits EH, Kim HS: Uterine fibroids: Diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgery-preliminary study. Radiology 236:196-203, 2005
47. Mardor Y, Roth Y, Ochershvilli A, et al: Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 6:136-142, 2004
48. DeVries AF, Kremser C, Hein PA, et al: Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56:958-965, 2003
49. Kamel IR, Bluemke DA, Ramsey D, et al: Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181:708-710, 2003
50. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96-102, 2001
51. Yeh E, Slanetz P, Kopans DB, et al: Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184:868-877, 2005
52. Drew PJ, Kerin MJ, Mahapatra T, et al: Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 27:617-620, 2001
53. Burcombe RJ, Makris A, Pittam M, et al: Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 38:375-379, 2002
54. Rieber A, Brambs HJ, Gabelmann A, et al: Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12:1711-1719, 2002
55. Meisamy S, Bolan PJ, Baker EH, et al: Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting response with in vivo (1)H MR spectroscopy - A pilot study at 4 T. Radiology 233:424-431, 2004
56. Picci P, Sangiorgi L, Rougraff BT, et al: Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 12:2699-2705, 1994